Homa F L, Brideau R J, Lehman D J, Thomsen D R, Olmsted R A, Wathen M W
Upjohn Company, Kalamazoo, Michigan 49001.
J Gen Virol. 1993 Sep;74 ( Pt 9):1995-9. doi: 10.1099/0022-1317-74-9-1995.
A cotton rat model of experimental human respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (PIV-3) infection was used to examine the efficacy of FRHNP, a novel chimeric glycoprotein which contains the extracellular regions of the fusion glycoprotein of RSV and the attachment glycoprotein of PIV-3, as a single subunit vaccine against these two viruses. This work was prompted by previous cotton rat studies that demonstrated that the major protective antigens of the two viruses were these glycoproteins. FRHNP was expressed in insect cells using a recombinant baculovirus. Vaccination with FRHNP resulted in induction of both RSV and PIV-3 neutralizing antibody and doses of 200 ng completely protected rats from either RSV or PIV-3 challenge. These results demonstrate that in the cotton rat animal model a single chimeric glycoprotein can be an effective vaccine against both RSV and PIV-3.
利用棉鼠实验性人类呼吸道合胞病毒(RSV)和人类3型副流感病毒(PIV-3)感染模型,研究了一种新型嵌合糖蛋白FRHNP作为针对这两种病毒的单亚基疫苗的效力。该嵌合糖蛋白包含RSV融合糖蛋白的胞外区域和PIV-3附着糖蛋白的胞外区域。此前针对棉鼠的研究表明这两种病毒的主要保护性抗原就是这些糖蛋白,由此开展了本研究。使用重组杆状病毒在昆虫细胞中表达FRHNP。用FRHNP进行疫苗接种可诱导产生RSV和PIV-3中和抗体,200 ng的剂量能完全保护大鼠免受RSV或PIV-3攻击。这些结果表明,在棉鼠动物模型中,单一嵌合糖蛋白可以作为针对RSV和PIV-3的有效疫苗。